<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Substantial evidence supports the concept that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are organized in a cellular hierarchy with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells (<z:chebi fb="11" ids="17437,53115">CSC</z:chebi>) at the apex </plain></SENT>
<SENT sid="1" pm="."><plain>To date, the primary evidence for <z:chebi fb="11" ids="17437,53115">CSCs</z:chebi> derives from transplantation assays, which have known limitations </plain></SENT>
<SENT sid="2" pm="."><plain>In particular, they are unable to report on the fate of cells within the original human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Because of the difficulty in measuring <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> characteristics in patients, cellular organization and other aspects of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> dynamics have not been quantified directly, although they likely play a fundamental role in <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> and therapy response </plain></SENT>
<SENT sid="4" pm="."><plain>As such, new approaches to study <z:chebi fb="11" ids="17437,53115">CSCs</z:chebi> in patient-derived <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens are needed </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, we exploited ultradeep single-molecule genomic data derived from multiple microdissected <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> glands per <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, along with a novel quantitative approach to measure <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> characteristics, define patient-specific <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> profiles, and infer <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> ancestral trees </plain></SENT>
<SENT sid="6" pm="."><plain>We show that each <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is unique in terms of its cellular organization, molecular <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, time from <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e>, and rate of mutation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Importantly, we estimate <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> fractions between 0.5% and 4%, indicative of a hierarchical organization responsible for long-lived <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> lineages, with variable rates of symmetric cell division </plain></SENT>
<SENT sid="8" pm="."><plain>We also observed extensive molecular <z:hpo ids='HP_0001425'>heterogeneity</z:hpo>, both between and within individual <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> glands, suggesting a complex hierarchy of mitotic clones </plain></SENT>
<SENT sid="9" pm="."><plain>Our framework enables the measurement of clinically relevant patient-specific characteristics in vivo, providing insight into the cellular organization and dynamics of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, with implications for personalized patient care </plain></SENT>
</text></document>